Long-Term Health Outcomes of Lecanemab in Patients with Early Alzheimer’s Disease Using Simulation Modeling
Tóm tắt
Từ khóa
Tài liệu tham khảo
Alzheimer’s Association. 2021 Alzheimer’s disease facts and figures. Alzheimers Dement. 2021;17:327–406.
K. Kochanek, J. Xu, E. Arias. Mortality in the United States, 2019. NCHS Data Brief, No. 395. Hyattsville, MD: National Center for Health Statistics;2020.
Arvanitakis Z, Shah RC, Bennett DA. Diagnosis and management of dementia: review. JAMA. 2019;322:1589–99.
Cummings JL, Tong G, Ballard C. Treatment combinations for Alzheimer’s disease: current and future pharmacotherapy options. J Alzheimers Dis. 2019;67:779–94.
Cummings J, Fox N. Defining disease modifying therapy for Alzheimer’s disease. J Prev Alzheimers Dis. 2017;4:109–15.
Cummings J, Lee G, Zhong K, Fonseca J, Taghva K. Alzheimer’s disease drug development pipeline: 2021. Alzheimers Dement (N Y). 2021;7:e12179.
Food and Drug Administration, FDA grants accelerated approval for Alzheimer's drug. https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-drug. Published 2021. Accessed 16 Feb 2022.
Herring WL, Gould IG, Fillit H, et al. Predicted lifetime health outcomes for aducanumab in patients with early Alzheimer’s disease. Neurol Ther. 2021;10:919–40.
Eisai Inc., A study to evaluate safety, tolerability, and efficacy of lecanemab in subjects with early Alzheimer's disease. Clinicaltrials.gov. Published 2013. Updated 2021. Accessed 11 Feb 2022.
Zhou J, Irizarry MC, Kramer LD, et al. AHEAD 3–45 study: Preliminary screening and baseline characteristics from a placebo-controlled, double-blind study evaluating lecanemab in participants with preclinical Alzheimer’s disease and elevated (A45 trial) and intermediate (A3 trial) amyloid. Alzheimers Dement. 2021;17:e053143.
Lynch SY, Irizarry MC, Dhadda S, et al. Baseline characteristics for CLARITY AD: a phase 3 placebo-controlled, double-blind, parallel-group, 18-month study evaluating lecanemab (ban2401) in early Alzheimer’s disease. Alzheimers Dement. 2021;17:e054331.
Swanson CJ, Zhang Y, Dhadda S, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimers Res Ther. 2021;13:80.
Alzheimer's Disease Neuroimaging Initiative, Alzheimer's Disease Neuroimaging Initiative [homepage]. http://adni.loni.usc.edu/. Published 2017. Accessed 2 June 2021.
Kansal AR, Tafazzoli A, Ishak KJ, Krotneva S. Alzheimer’s disease Archimedes condition-event simulator: development and validation. Alzheimers Dement (N Y). 2018;4:76–88.
A. Tafazzoli, J. Weng, K. Sutton, et al. Validating simulated cognition trajectories based on ADNI against trajectories from the National Alzheimer's Coordinating Center (NACC) dataset. In: 11th edition of Clinical Trials on Alzheimer's Disease (CTAD); 2018; Barcelona, Spain.
Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14:535–62.
Petersen RC, Lopez O, Armstrong MJ, et al. Practice guideline update summary: mild cognitive impairment: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90:126–35.
Arias E. United States Life Tables, 2017. Natl Vital Stat Rep. 2019;68:1–66.
Andersen K, Lolk A, Martinussen T, Kragh-Sorensen P. Very mild to severe dementia and mortality: a 14-year follow-up—the Odense study. Dement Geriatr Cogn Disord. 2010;29:61–7.
Wimo A, Handels R, Winblad B, et al. Quantifying and describing the natural history and costs of Alzheimer’s disease and effects of hypothetical interventions. J Alzheimers Dis. 2020;75:891–902.
Neumann PJ, Hermann RC, Kuntz KM, et al. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer’s disease. Neurology. 1999;52:1138–45.
S. Cohen, C. Van Dyck, C. Mummery, et al. Baseline Embark data from Emerge, Enfate, and prime participants in the Embark re-dosing study. Clinical Trials on Alzheimer's Disease (CTAD) 2021; 2021; Boston, MA.
Landeiro F, Mughal S, Walsh K, et al. Health-related quality of life in people with predementia Alzheimer’s disease, mild cognitive impairment or dementia measured with preference-based instruments: a systematic literature review. Alzheimers Res Ther. 2020;12:154.
Neumann PJ, Kuntz KM, Leon J, et al. Health utilities in Alzheimer’s disease: a cross-sectional study of patients and caregivers. Med Care. 1999;37:27–32.
Xu R, Insinga RP, Golden W, Hu XH. EuroQol (EQ-5D) health utility scores for patients with migraine. Qual Life Res. 2011;20:601–8.
Mesterton J, Wimo A, By A, Langworth S, Winblad B, Jonsson L. Cross sectional observational study on the societal costs of Alzheimer’s disease. Curr Alzheimer Res. 2010;7:358–67.
Institute for Clinical and Economic Review (ICER), A guide to ICER's methods for health technology assessment. https://icer.org/wp-content/uploads/2021/01/ICER_HTA_Guide_102720.pdf. Published 2020. Accessed
M. Di Carlo, D. Giacomazza, P.L. San Biagio, Alzheimer's disease: biological aspects, therapeutic perspectives and diagnostic tools. J Phys Condens Matter 2012;24:244102.
Guo S, Getsios D, Revankar N, et al. Evaluating disease-modifying agents: a simulation framework for Alzheimer’s disease. Pharmacoeconomics. 2014;32:1129–39.
Ito K, Chapman R, Pearson SD, Tafazzoli A, Yaffe K, Gurwitz JH. Evaluation of the cost-effectiveness of drug treatment for Alzheimer disease in a simulation model that includes caregiver and societal factors. JAMA Netw Open. 2021;4:e2129392.
Synnott PG, Whittington MD, Lin GA, Rind DM, Pearson SD. The effectiveness and value of aducanumab for Alzheimer’s disease. J Manag Care Spec Pharm. 2021;27:1613–7.